[Evaluation and correction of the pain syndrome in premature newborns with CNS infringement].
Premature newborn may feel different kinds of pain, thus incomplete diagnostics and unjustified therapy may lead to unfavourable physiological effects. All the pain feelings that a child experiences are acute and recurrent or persistent leading to a pain syndrome if there is no intervention. Currently a huge arsenal of pharmacological drugs is available to control pain. There are a lot of researches described in the literature on the effectiveness of the pharmacodynamics, pharmacokynetics and complications related to administration of different analgetics in newborns. However the unfavorable complications identified prevent their use in newborns. Analgesic effect can be made not only by proper analgetics, but combined homeopathic medications as well. One of such medications, which has no side effects is traumel S. The current paper reflects outcomes of the clinical research took place over the 79 pre-term newborns with infringement of the CNS who are subject of a big number of the prescribed treatment manipulation and procedures whereas most of them are quite painful. There is necessity of applying anesthesia treatment for avoiding clinical and biochemical consequences of the pain syndrome. Application of the traumel C intramuscularly or traumel C ointment per os just before and during painful manipulation affect drop pain level of a newborn. Appreciation of pain is subject to the level of CNS lesions because during severe disorders behavioral reaction to pain is certainly reduced. Premature newborns from control group, in the dynamics of neonatal period, manifested reliable reduction (R<0,05) of neurokinin A from 17.52 to 2.08 ng/ml, substance P from 2.5 to 0.3 n/ml compare to seek newborns. During comparison of the results it was revealed that premature newborns, with hypoxemic-ischemic lesion of CNS, treated based on traditional allopathic therapy from the first day of life, manifest significantly high level of neurokinin A and substance P, maintained until the end of first month of life. It was also determined that during the use of allopathic therapy on 7-10th days of life neurokinin A and substance P form 76.86 and 14.46 ng/ml respectively, confirming the development of pain syndrome.